Cost per responder analysis of ustekinumab and etanercept for moderate to severe plaque psoriasis

By Martin Silas   Feldman Steven R.   Augustin Matthias   Szapary Philippe   Schenkel Brad  

Journal of Dermatological Treatment, Vol. 22, Iss. 3, 2011-06 ,pp. : 138-143

Informa Healthcare

Access to resources Recommend Favorite

Impact of adalimumab treatment on patient-reported outcomes: Results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis

By Revicki Dennis   Willian Mary Kaye   Menter Alan   Gordon Kenneth   Kimball Alexa   Leonardi Craig   Langley Richard   Kimel Miriam   Okun Martin  

Journal of Dermatological Treatment, Vol. 18, Iss. 6, 2007-01 ,pp. : 341-350

Informa Healthcare

Access to resources Recommend Favorite

The efficacy and safety of etanercept when used with as-needed adjunctive topical therapy in a randomised, double-blind study in subjects with moderate-to-severe psoriasis (the PRISTINE trial)

By Strohal Robert  

Journal of Dermatological Treatment, Vol. 24, Iss. 3, 2013-06 ,pp. : 169-178

Informa Healthcare

Access to resources Recommend Favorite

Topical TrkA Kinase Inhibitor CT327 is an Effective, Novel Therapy for the Treatment of Pruritus due to Psoriasis: Results from Experimental Studies, and Efficacy and Safety of CT327 in a Phase 2b Clinical Trial in Patients with Psoriasis

By Roblin David   Yosipovitch Gil   Boyce Brent   Robinson John   Sandy James   Mainero Valentina   Wickramasinghe Ro   Anand Uma   Anand Praveen  

Acta Dermato-Venereologica, Vol. 95, Iss. 5, 2015-05 ,pp. : 542-548

Medical Journals Limited

Access to resources Recommend Favorite

Methotrexate versus hydroxycarbamide (hydroxyurea) as a weekly dose to treat moderate-to-severe chronic plaque psoriasis: A comparative study

By Ranjan Nitin   Sharma Nand Lal   Shanker Vinay   Mahajan Vikram   Tegta Gita Ram  

Journal of Dermatological Treatment, Vol. 18, Iss. 5, 2007-01 ,pp. : 295-300

Informa Healthcare

Access to resources Recommend Favorite